Dr. Simó Schwartz Jr. assumes the general direction of the Blood and Tissue Bank after 16 years at VHIR
Dr. Simó Schwartz Jr. has been appointed as the new general director of the Blood and Tissue Bank, replacing Dr. Enric Argelagués, who leaves his position today, March 1, after 17 years in the management (1993 – 2002 and 2013 – 2021). Argelagués was the promoter of the unification of blood banks that began in
Vall d’Hebron leads a clinical study testing the use of nanoparticles for the treatment of locally advanced pancreatic cancer
Nanomedicine has emerged as a potential therapy for pancreatic cancer, a disease with a 5-year survival rate as low as 5%. The international project NoCanTher was launched in 2016 to test the use of magnetic nanoparticles in treating locally advanced pancreatic cancer. NoCanTher enters its final phase with the start-up of a clinical study led
A study by Vall d’Hebron suggests a new strategy for the treatment of colorectal cancer
The research group on CIBBIM-Nanomedicine, Drug Delivery and Targeting of the Vall d’Hebron Research Institute (VHIR) has recently participated in a study with the aim of finding a useful treatment to combat colorectal cancer, but also to eradicate cancer stem cells. The study notes that nanotechnology-based therapies emerge as promising therapeutic strategies for a wide
Created BSURE Medical, a new spin-off of the VHIR
The creation of BSURE Medical represents the culmination of the valuation and transfer strategy carried out by the VHIR Innovation Unit of a research project of which Dr. Jaume Alijotas Reig and Dr. Simo Schwartz Jr are the main researchers and promoters. The groups of Dr. Alijotas and Dr. Schwartz Jr have developed a procedure
Patented a peptide that allows faster internalization of drugs within cells and the design of more effective therapeutic nanoconjugates
The membrane of a cell is an effective barrier that makes it difficult to deliver molecules, such as therapeutic compounds, in a targeted manner. In recent years, various strategies have been developed to get the molecules inside the cell, but in general, the methods developed are still low in efficacy and/or toxicity. «The use of
Three researchers at VHIR receive a grant from the Spanish Association Against Cancer
The Spanish Association Against Cancer (AECC) presented today, within the framework of World Cancer Research Day, the resolution of the grants to promote research against cancer. Among the selected candidates, there are three researchers working in oncology research at Vall d’Hebron Institute of Research (VHIR): Dr. Laura Mondragón, Dr. Eva Colás and Dr. Trond Aasen.
Cerium oxide nanoparticles may improve hepatocellular carcinoma prognosis
Hepatocellular carcinoma is the most common liver cancer and ranks third in the world in terms of mortality. Its appearance is related to the hepatitis B and C viruses, alcoholism, metabolic diseases of the liver and exposure to certain toxins. Although its molecular mechanisms have been described in detail, no effective treatment is currently available
Managing Zileuton by means of polymeric micelles significantly reduces the tumor stem cells of breast cancer within the tumor and in the bloodstream
The CIBBIM-Nanomedicine. Drug Delivery and Targeting Group of the Vall d’Hebron Research Institute (VHIR) has conducted a study to measure the effectiveness of Zileuton ™, a drug that is indicated for the treatment of asthma, administered through micelles. The polymeric against tumor stem cells in triple negative breast cancer, one of the most aggressive tumors.
New antitumoral drug release strategy created for breast cancer treatment
Researchers from the CIBBIM-Nanomedicine Drug Delivery and Trageting of the Vall d’Hebron Research Institute (VHIR) and CIBER-BBN with Dr. Ibane Abasolo at the head, have studied the viability of the bacterial inclusion bodies as a method of distribution of two antitumor proteins, p31 and Omomyc, against breast cancer. The study, published in Advanced Science, has
Clinical Nanomedicine and Advanced Therapies Research Centre. The Pharmacokinetics of Nanoparticles
The Nanoparticle Design and Pharmacodynamics group focuses on the synthesis, characterisation and applications of inorganic nanoparticle engineering in the field of medicine. The group’s aim is to design nanoparticles that can interact with biological systems in a specific way. The group is headed up by Professor Víctor Puntes, ICREA (Catalan Institution for Research and Advanced
The Dra. Anna M. Meseguer awarded by the College of Biologists of Catalonia
Yesterday evening, on the occasion of the Biologist’s Day, Dr. Anna Meseguer picked up the Research and Investigation Prize awarded by the College of Biologists of Catalonia in recognition of her contribution to scientific advances and the contribution to increasing the professional prestige of the profession. The Auditori of l’Aquàrium in Barcelona was the venue
Safe-N-Medtech kicks off in Bilbao
The Safe-N-Medtech initiative just kicked off last week in Bilbao, in a meeting hosted by Osteba, the HTA Unit of the Health Ministry of the Basque Country (Spain) in collaboration with BIOPRAXIS-BIOKERALTY. The project is coordinated by TECNAN (an SME from Navarra, with great experience in Nano products), together with BIOPRAXIS-BIOKERALTY (the research branch of
How former Elsevier editors started a community-led publisher and launched their first OA journal
After serving as editor-in-chief of Nanomedicine: Nanotechnology, Biology and Medicine for over seven years, Lajos Balogh knew that he had the skills and expertise needed to run an academic journal. An ardent open access (OA) advocate, Balogh also knew that he wanted to promote open science in the field of nanomedicine. So when his editorship
Highlighted presence of VHIR researchers at the 11th Jornada de Recerca de l’ICS
On May 23, 2019, the Centre Tarraconense El Seminari will host the 11th Research Day organized by the Catalan Health Institute involving several researchers from the Vall d’Hebron Research Institute (VHIR). This year, is dedicated to pediatric research. The Conference will be focused on two highly topical aspects: obesity and minority diseases. In the first
Second mini-symposium on Cancer Research Omics
The Vall d’Hebron Research Institute’s Oncology Department (VHIR) has organized the second mini-symposium ‘OMICs in Cancer Research’ in which speakers from different institutions and countries, reviewed the current state of «Omics» in the research of cancer. The symposium was held on the afternoon of March 19 at the Vall d’Hebron University Hospital with a full
March 31, World Colorectal Cancer Day
On the occasion of World Colorectal Cancer Day, this Sunday, March 31, CIBBIM-Nanomedicine. Biomedical Research in Digestive Tract Tumors of the Institut de Recerca Vall d’hebron (VHIR) wants to raise awareness among the population about the importance of early diagnosis and the acquisition of healthy habits to prevent its appearance. In Spain, colorectal cancer is
Vall d’Hebron organizes a seminar on Lysosomal Rare Disorders: Focus on Fabry Disease
Next Monday, November 19, Vall d’Hebron will hold a seminar focused on Lysosomal Rare Disorders: Focus on Fabry Disease. The seminar is part of the Rare Diseases Program at the Vall d’Hebron Campus, in collaboration with the European Commission, the Center for Biomedical Research Network on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) and the CIBBIM-Nanomedicine at
VHIR researchers receive European funding for liver disease research
Dr. Joan Genescà, head of the Liver Diseases research group and Dr. María Martell, group researcher and head of the Advanced Liver Disease laboratory, from the Liver Diseases group at VHIR, have received funding for a European research project in the Joint Call for transnational projects in nanomedicine, within the framework of the European network
The EMA designates a new orphan drug for Fanconi anemia in whose development VHIR has participated
The European Commission, upon proposal from the European Medicines Agency (EMA), has designated Gefitinib as an orphan drug for Fanconi anemia. This orally administered product is currently indicated for the treatment of lung cancer. The studies of the Biomedical Research Center Network on Rare Diseases (CIBERER), the Genetic Service and the Hospital de Sant Pau
CIBBIM Nanomedicine awarded at the National Congress of Paediatric Nephrology
Pre-doctoral researcher Mónica Vall, from the research group in Renal Physiopathology – CIBBIM Nanomedicine led by Dr. Anna Meseguer, won the prize for the best poster – short communication from the XLIII National Congress of Paediatric Nephrology, held in Valencia, for her work «Establishment of the protocol for isolating urinary exosomes in patients with familial
Dr. J. Raúl Herance, appointed Co-chair of the Spanish Group of the European Molecular Imaging Society
Recently, Dr. J Raúl Herance, co-head of the Molecular Medical Imaging group at the Vall d’Hebron Research Institute (VHIR) has been elected to the position of Co-chair of the Spanish Group of the European Molecular Imaging Society. It will occupy this position for two years with Dr. Beatriz Salinas Rodriguez, of the Health Research Institute
A new European project awarded to the CIBBIM-Nanomedicine of the VHIR converts the Vall d’Hebron Campus into the health institution with the highest number of active research projects in Nanomedicine of Europe
For the first time, the Vall d’Hebron Campus has a FET Innovation (Future and Emerging Technologies) project that has been awarded within the Horitzo 2020 program to the CIBBIM-Nanomedicine. Drug Delivery and Targeting research group. Addressing and Pharmacological Release that leads Dr. Simó Schwartz Jr. The EVO-NANO project aims to develop a virtual simulator, called
The EVO-NANO project will allow testing the behavior of nanoparticles within a tumor
The CIBER-BBN-CIBBIM group, led by Dr. Simó Schwartz, coordinating NANBIOSIS U20. In Vivo Experimental Platform has been granted a FET Innovation project (Future and Emerging Technologies) within the Horizon 2020 program. The EVO-NANO project aims to develop a virtual simulator, called NanoDoc, which will allow testing the behavior of nanoparticles within a tumor and with
April, Fabry disease awareness month
The Fabry International Network (FIN) association has established the month of April as the «month of Fabry» to raise awareness and educate about this disease, a rare, progressive and with multi-organ involvement pathology. Fabry disease is a metabolic disease that is produced by a deficiency of the Lysosomal enzyme Alpha galactosidase. It is transmitted on
Dr. Simó Schwartz Jr, appointed editorial Board member of the Precision Nanomedicine journal
In the coming days the Precision Nanomedicine journal will see the light, in its online version that is already being finalised. Dr. Simón Schwartz Jr, director of CIBBIM-Nanomedicine, is one of only two Spanish researchers who are part of the editorial board of the journal. The rest of editors belong to the United States, Australia,
The team of Dr. Simó Schwartz Jr gets a polymeric nanomedicine which facilitates concurrent therapies of pharmacological and gene silencing
One of the main problems that nanomedicine must face is the improvement of drugs transport and release systems to the correct place of action. And in particular, to take nucleic acids to the right target cells. The team led by Dr. Simó Schwartz Jr, director of the CIBBIM-nanomedicine has managed to create a micelle formed
The Area of Functional Validation & Preclinical Research of CIBBIM-Nanomedicine obtains the ISO 9001:2008 certification of Quality Management System
This January, the Area of Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine has obtained the ISO 9001:2008 certification of Quality Management Systems for functional validation, preclinical development and/or histological processing services for agents with therapeutic or diagnostic activity, especially those with a nanotechnology base. The certification audit was carried out in May 2017 by
Asdent donates more than 114,000 euros for the investigation of Dent’s disease in Vall d’Hebron
Asdent (Association of Dent Disease) has delivered 114,978.55 euros to the Vall d’Hebron Research Institute (VHIR) to continue researching this disease. The pathology of Dent is a hereditary minority disease linked to the X chromosome and characterized by alterations of the proximal renal tubule that result in proteinuria, hypercalciuria and nephrocalcinosis. The patients expel in
Proven the use of the polyurethane nanoparticle and poliurea (PUUa) for the improvement of therapy against cancer
The national consortium led by the research group of Addressing and Drug Release CIBBIM – Nanomedicine of the Vall d’Hebron Research Institute (VHIR) and led by Dr. Ibane Abasolo, has shown improvement in the effectiveness and specificity of targeted therapy against cancer through the use of polyurethane-polyurea nanocapsules (PUUa), a nanoparticle with a proven targeted
Proven that a protein produced by the kidney could become a therapeutic target for the metabolic syndrome
A study led by Dr. Anna Meseguer, chief of the group of research CIBBIM-Nanomedicine Renal Pathophysiology of the Vall d’Hebron Research Institute (VHIR), has showed the role of the KAP protein in the control of the development of the metabolic syndrome produced by following a diet rich in fats. The creation of a model based
Learned lessons from a primary immunodeficiency: a study by Dr. Joan Sayos
Last September, the journal of Immunology published a new article in the series «The Pillars of Immunology», which reminds the classics that have promoted the knowledge of modern immunology. In this case, the study published has been based in the paper published in 1998 by Dr. Joan Sayos, head of the research group CIBBIM –
6,8€ Million Granted to nTRACK Horizon 2020 Project, in which VHIR participates, to study multimodal nanoparticles as contrasts imaging agents for muscle regeneration
The European Union has awarded a grant of 6,8 million Euro to nTRACK collaborative project, which will officially be launched on the 16th of October in Barcelona. The goal of the nTRACK project is to develop a highly sensitive multimodal nano-imaging agent in compliance with current regulatory framework. It will enable non-invasive, quantitative and longitudinal
CaixaImpulse selects a VHIR project to combat multiresistant infections
El projecte ThermoShot™-FlashShot™: Nova tecnologia per combatre les infeccions multiresistents o les produïdes per dispositius mèdics que produeixen biopel·lícules forma part dels 23 treballs seleccionats en la tercera convocatòria del Programa CaixaImpulse. Està liderat pel Dr. Joan Gavaldà Santapau, coordinador del Laboratori de Resistències Antibiòtiques del Grup de Recerca en Malalties Infeccioses de Vall d’Hebron
NANOMEDICINE AND FUTURE, explained by Simó Schwartz, Director of U20 of NANBIOSIS
NANBIOSIS-U20 Scientific Director, Simó Schwartz, speaks about Nanomedicine in an interview publish in http://www.quimicaysociedad.org. NANBIOSIS is an Singular Scientific Technological Infrastructure (ICTS) that provides a complete service for the production and characterization of nanomaterials, biomaterials and systems in biomedicine, including the design and production of biomaterials and nanomaterials and their nanoconjugates, and the characterization of
The EU-NCL network will support a project of nanomedicine for prostate cancer
The European Nanomedicine Characterisation Laboratory (EU-NCL) has selected a project from VHIR intended to develop a therapeutic nanoconjugate that improves the treatment of prostate cancer. The project is coordinated by Dr. Simó Schwartz Jr, director of CIBBIM-nanomedicine, and Dr. Ibane Abasolo, from CIBBIM-Nanomedicine. Drug Delivery and Targeting group at VHIR, and Dr. María Jesús Vincent,
Nanoparticles against cancer in the Live Research Fair
Can we improve the treatment of cancer with the help of nanoparticles? How can we help improve the effectiveness of a drug? Which treatment works best? And how can we test it? These are some of the questions that the group if Functional Validation and Preclinical Research (FVPR) has responded, from the research group CIBBIM-Nanomedicine.
Tumour cells are dependent on fat to start metastasis
A study headed by Salvador Aznar Benitah, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona), and published today in Natureidentifies metastasis-initiating cells through a specific marker, namely the protein CD36. This protein, which is found in the membranes of tumour cells, is responsible for taking up fatty acids. CD36 activity and dependence
VHIR participates in a European project against Fabry disease
The Drug Delivery and Targeting group from the CIBBIM-Nanomedicine at VHIR, led by Dr. Simó Schwartz Jr., participates in a new European project, which aims the innovation and improvement in the treatment for Fabry disease, a rare condition X-linked which affects 1 in 7.000 people approximately. The project is awarded with 5,8 milion in the
Customized prosthesis made for patients by a digital planning platform
The Oral and Maxillofacial Surgery Service at Vall d’Hebron University Hospital has a new tools to make the recovery of patients easier. Together with the company Avinent, this service developed a new digital planning platform, pioneer, which allows surgeons to prepare the intervention and also allows them to contact engineers and technical staff who design
The laboratory of Dr. Abasolo receives the visit of a future investigator
Artur Aymar is sure he wants to study Biomedical Engineering; for this reason, he is happy to perform the research work in one of the VHIR’s laboratories as it is the opportunity to learn first-hand “what kind of research takes place in a real lab”. Artur is 16 years old and he is studying 2nd
Dr. Simó Schwartz Jr has been appointed as a member of the advisory board of the EU-NCL
Dr. Simó Schwartz Jr, director of the CIBBIM-Nanomedicine of the Vall d’Hebron Institute of Research (VHIR), has been appointed as a member of the advisory board of the Nanomedicine Characterisation Laboratory (EU-NCL). Dr. Schwartz will collaborate with the EU-NCL defining the objectives as well as setting up the strategic plan and director plan. The EU-NCL
La Masia and the AECC promoting a solidarity oil for breast cancer research
The Spanish Association Against Cancer (AECC) and La Masía have presented today the initiative «Aceite de Oliva Solidario» (Solidarity Olive Oil). The goal of the challenge – which starts today and ends on October 19, World Day Against Breast cancer – is to fund with 50,000 euros the breast cancer research project directed by Dr.
Asdent donates more than 120,000 euros to raise funds for the Dent’s disease at Vall d’Hebron
Nacho is a 6-year-old child who was diagnosed when he was 3 with the Dent’s disease; a rare untreatable disease which may result in renal failure. Since the diagnosis, his parents have not stop to reverse this situation getting researchers to investigate in order to curb the disease. Now, 3 years after the diagnosis, they
Dr. Simó Schwartz, Scientific, appointed president of the European Society for Nanomedicine (ESNAM)
The objectives of ESNAM are to promote nanomedicine research and facilitate the exchange of knowledge among its members (currently, about 800 members). According to Dr. Simó Schwartz “the dissemination of specialized infrastructure in nanomedicine, like NANBIOSIS, among members of the society and its utilities is also an object of ESNAM. This is intended to strengthen
VHIR brings nanomedicine to the Science Festival
The Vall d’Hebron Research Institute (VHIR) participated once again in the Science Festival, which this year has reached its 10th edition. Dr. Víctor Puntes, head of the group of Design and Pharmacodynamics of Nanoparticles, gave a talk, with two experiments, to explain the benefits of nanomedicine on the health of people. As the festival program
VHIR presented the results of three projects of the TV3’s Marathon 2010
On Wednesday 15 June was held the Symposium on acquired spinal cord and brain injuries, in which have been presented the results of the 30 projects funded in the 2010 edition of the TV3 Marathon. Of these projects, three were carried out at the Vall d’Hebron Research Institute (VHIR). The Institute’s director, Dr. Joan Comella,
The Association for Familial Hypomagnesemia donates once again 15000 € for the research of this disease
For the second year in a row, the Association for Information and Research of Familial Hipomagnesemia (Hipofam) has given 15000 euros to the research group on Renal Physiopathology of Vall d’hebron Research Institute (VHIR) to investigate this rare genetic disease. The funds have been collected through numerous charitable activities, such as paddle tennis tournaments, exhibitions
Dr. Schwartz Jr participates in a European nanomedicine project for pancreatic cancer
The Drug Delivery and Targeting group from the CIBBIM-Nanomedicine at VHIR, led by Dr. Simó Schwartz Jr., participates in a new European project, called NoCanTher, which aims to develop treatments with nanomedicine for pancreatic ductal carcinoma. The project is awarded with 7 million euros in the Horizon 2020 program of the European Commission, and involves
Dr. Anna Meseguer receives grant from the American Association for Cancer Research
Dr. Anna Meseguer, head of the Kidney Physiopathology group at the Vall d’Hebron Institute of Research (VHIR), has received the 2016 Research Grant for Immunotherapy in Kidney Cancer of the American Association for Cancer Research, endowed with 250,000$ for two years. Her research project, entitled “Could TIM-1 constitute a new target for renal carcinoma immunotherapy?”,
Taking care of your kidneys, and also of the youngest ones’
Renal disease, those that affect the kidneys are not an issue just for adults. Younger children also suffer. A reality that sometimes is hidden and has led to devote this year’s World Kidney Day to preventing diseases that affect children. Under the slogan Kidney Disease and Children, act quickly to prevent it, the Spanish Association
Dr Simó Schwartz Jr is appointed editor of the European Journal of Nanomedicine
Dr Simó Schwartz Jr, director of the CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VHIR), has been appointed member of the editorial board of the European Journal of Nanomedicine. VHIR’s researcher will review some of the manuscripts submitted to the prestigious scientific journal for the next two years. The journal focuses on the spectrum from
Three VHIR researchers receive three important European grants
Dr. Simó Schwartz Jr, head of the CIBBIM-Nanomedicine Drug Delivery and Targeting group, Dr. Diego Arango, head of the CIBBIM-Nanomedicine Biomedical Research in Digestive Tumors group, and Dr. Mar Hernández-Guillamón, principal investigator of the Neurovascular Diseases group at Vall d’Hebron Institute of Research (VHIR), have been granted with three important European projects. The first two
New methodology to improve the drug response of breast and colon cancer with nanomedicine
Researchers from the Drug Delivery and Targeting group of the CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VIHR), have evidenced that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. To be able to study the efficacy of the nanomedicines, researchers have developed a novel fluorescent model that allowed them to visualize
VHIR inaugurates the 2nd edition of the Master’s Degree in Translational Biomedical Research
On September 29th, Vall d’Hebron Institute of Research (VHIR) celebrated the opening day of the 2nd edition of the Official Master’s Degree in Translational Biomedical Research and the closing of the 1st edition, with the diploma award ceremony. Dr. Manel Esteller, director of the Cancer Epigenetics and Biology Program of the Bellvitge Biomedical Research Institute
VHIR receives two grants from the AECC to investigate stomach cancer and melanoma
The Vall d’Hebron Research Institute (VHIR) has received two projects in the last call of the Associación Española Contra el Cáncer (AECC) to investigate stomach cancer and malignant melanoma. The projects, worth 1,200,000 euros each, are led by Dr. Diego Arango, group leader of the Molecular Oncology Nanomedicine CIBBIM-VHIR, and Dr. Maria S. Soengas, from
The artist Josep Moscardó collaborates with VHIR by donating his Montjuïc Nit work
“Montjuïc nit” is the artist’s Josep Moscardó personal perspective of a set of emblematyc areas of Barcelona such as Montjuïc Hill, the Olympic ring on Montjuïc, the Paral·lel or the Port. Moscardó has donated a silk-screen printing edition of his work with a handwritten signature and numbering in order to help fundraising for research on
VHIR researchers validate a new therapeutic target for colorectal cancer treatment
Researchers from the Group of Molecular Oncology CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VHIR) have validated a gene, called PPOX, as a new therapeutic target against colorectal cancer. Furthermore, this study opens the door to the validation of more targets, as PPOX is only one of the 966 genes that researchers have found overexpressed
VHIR researchers presented the results funded by the Marató of 2009 devoted to rare diseases
On Monday afternoon, 20 research projects funded by La Marató 2009 devoted to rare diseases were presented in the 16th Symposium La Marató of TV3, at the Institut d’Estudis Catalans’ facilities. There were researchers from Vall d’Hebron, who had participated in three of the projects. Inhibition of the Notch’s pathway as a therapeutic target in
VHIR proposals for Sant Jordi
Here you have our three recommendations for this Sant Jordi’s Day: ‘En Roc al Planeta Mascareta’, ‘Nano-Oncology, the Turning Point’ and ‘Aians’. These three books are written by professionals from Vall d’Hebron Hospital. En Roc al Planeta Mascareta Roc is a kid who after escaping from the paws of a terrible dragoon (the disease), with
Possible new strategies to combat epithelial metastatic cancer have been described
An article published by researchers from the School of Pharmacy of the University of Lisbon and from the Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine) from the Vall d’Hebron Research Institute (VHIR) includes the latest discoveries in the field of epithelial metastatic cancer and considers the possibility of opening new therapeutic fronts for
